发明申请
- 专利标题： Treatment of cardiomyopathy and of endothelial dysfunction
- 专利标题（中）： 治疗心肌病和内皮功能障碍
-
申请号： US11147492申请日： 2005-06-07
-
公开(公告)号： US20050276785A1公开(公告)日： 2005-12-15
- 发明人: Georg Groetzbach , Joachim-Friedrich Kapp , Uwe Kuehl , Heinz-Peter Schultheiss , Olaf Sowade , Claus-Steffen Stuerzebecher
- 申请人： Georg Groetzbach , Joachim-Friedrich Kapp , Uwe Kuehl , Heinz-Peter Schultheiss , Olaf Sowade , Claus-Steffen Stuerzebecher
- 申请人地址： DE Berlin
- 专利权人： Schering Aktiengesellschaft
- 当前专利权人： Schering Aktiengesellschaft
- 当前专利权人地址： DE Berlin
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; A61K38/21
摘要：
The present invention relates to pharmaceutical compositions comprising a therapeutically effective dose of an isolated interferon (IFN) or IFN mutein for treatment of cardiomyopathy and of endothelial dysfunction, and to methods of treating cardiomyopathy and methods of treating endothelial dysfunction using such pharmaceutical compositions. Particularly, the pharmaceutical compositions of the present invention comprise a therapeutically effective dose of an isolated, human IFN, or IFN mutein that is a variant of an isolated human IFN, e.g., an isolated, native, human IFNβ or an isolated, native, human IFNα.